Compare Natera Inc. Common Stock (NTRA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Weibo Corp — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Weibo Corp trades at $6.43 (market cap $1.61B). The key difference: Natera Inc. Common Stock is far larger — about 35.4× Weibo Corp's market cap, and Weibo Corp pays a 9.3% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Weibo Corp for 103 Days on average.
| NTRA | WB | |
|---|---|---|
Market Cap | $57.03B | $1.61B |
Volume | 1,131,157 | 585,008 |
Sector | Health | Media |
52-Week High | $425.64 | $11.52 |
52-Week Low | $179.42 | $6.33 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $56.18B | $841.53M |
Dividend Yield | — | 9.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Weibo (WB) trades at $6.51, down 0.53% with bearish technical signals despite attractive valuation metrics including a P/E of 5.42 and P/B of 0.4. The company reported Q2 2026 EPS of $0.38, beating expectations, but faces declining user metrics and advertising revenue challenges. Cash flow trends show volatility with a significant net outflow in 2024 followed by recovery in 2025.
WB presents as a deep-value opportunity with strong profitability margins but faces growth headwinds from user engagement declines and competitive pressures. Analyst sentiment is mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
